Source:http://linkedlifedata.com/resource/pubmed/id/17450472
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2007-4-23
|
| pubmed:abstractText |
CYP2C19*2(G681A), CYP2C19*3(G636A), CYP2D6*4(C188T), CYP2D6*2(C2938T, G4268C), CYP3AP1*3- G44A and CYP3A5*3(A22893G) are the most common polymorphisms detected among Chinese that may influence the efficacy of vinorelbine-based therapies to treat non-small-cell lung cancer (NSCLC). We detected the genotypes of these polymorphisms by PCR-RFLP in 59 patients with NSCLC and assessed their responses to vinorelbine. CYP2D6*4(C188T), CYP3AP1*3 (G -44 A) and CYP3A5*3 were found to be associated with response to vinorelbine. For the 2D6*4 polymorphism, the 18 of 32 (56.25%) patients with homozygous (C/C) responded to this therapy, while 6 of 27 (22.22%) of those heterozygous (C/T) at this site responded. (chi2=5.68, p < 0.05) For the 3AP1*1/*3 polymorphism, 12 of 42 (28.57%) patients with homozygous (A/A) responded, while 12 of 17 (70.59%) with heterozygous (A/G) and homozygous (G/G) responded (chi2=7.19, p < 0.01). CYP3A5*3 polymorphism has a result corresponding to 3AP1*3 polymorphism. Other polymorphisms were not associated with response to vinorelbine. No significant difference in toxicity and survival was observed according to SNP genotype.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0284-186X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
46
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
361-6
|
| pubmed:dateRevised |
2009-5-12
|
| pubmed:meshHeading |
pubmed-meshheading:17450472-Adult,
pubmed-meshheading:17450472-Aged,
pubmed-meshheading:17450472-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:17450472-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:17450472-China,
pubmed-meshheading:17450472-Cytochrome P-450 Enzyme System,
pubmed-meshheading:17450472-Female,
pubmed-meshheading:17450472-Gene Frequency,
pubmed-meshheading:17450472-Genotype,
pubmed-meshheading:17450472-Humans,
pubmed-meshheading:17450472-Lung Neoplasms,
pubmed-meshheading:17450472-Male,
pubmed-meshheading:17450472-Middle Aged,
pubmed-meshheading:17450472-Neoplasm Staging,
pubmed-meshheading:17450472-Polymerase Chain Reaction,
pubmed-meshheading:17450472-Polymorphism, Genetic,
pubmed-meshheading:17450472-Polymorphism, Restriction Fragment Length,
pubmed-meshheading:17450472-Polymorphism, Single Nucleotide,
pubmed-meshheading:17450472-Predictive Value of Tests,
pubmed-meshheading:17450472-Survival Analysis,
pubmed-meshheading:17450472-Treatment Outcome,
pubmed-meshheading:17450472-Vinblastine
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer.
|
| pubmed:affiliation |
Key Laboratory of Ministry of Health for Biotech-Drug, Shandong Medicinal and Biotechnology Center, Shandong Academy of Medical Sciences, 89 Jingshi Road, Jinan, Shandong Province, 250062, China.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|